Physician profile
Peter Van
NPI 1134330400
$8,017.47
in general payments reported to CMS, 2019-2025
33 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $263 · 2021: $1,254 · 2022: $1,605 · 2023: $1,259 · 2024: $1,314 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,302 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,302.35 |
| Education | $114.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,186.84 | 2022-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $1,003.27 | 2019-2025 | Lokelma, Farxiga, Evusheld |
| Travere Therapeutics, INC. | $547.37 | 2022-2025 | Filspari |
| Melinta Therapeutics, LLC | $493.96 | 2019-2024 | Kimyrsa, Rezzayo |
| Otsuka America Pharmaceutical, INC. | $448.29 | 2021-2025 | Jynarque |
| Amgen INC. | $406.83 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Mallinckrodt Hospital Products INC. | $393.73 | 2021-2025 | Acthar, Terlivaz |
| Paratek Pharmaceuticals, INC. | $374.99 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $354.61 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $343.37 | 2021-2025 | |
| Abbvie INC. | $250.00 | 2023-2024 | Dalvance |
| Shionogi INC | $244.24 | 2021-2025 | Fetroja |
| Horizon Therapeutics Plc | $233.61 | 2022-2023 | Krystexxa |
| Akebia Therapeutics INC | $180.11 | 2021-2023 | Auryxia |
| Allergan, INC. | $175.86 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $131.72 | 2021-2025 | |
| Vifor Pharma, INC. | $129.52 | 2021-2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $125.60 | 2021-2025 | Rayaldee |
| Viiv Healthcare Company | $125.00 | 2025 | Cabenuva |
| Aurinia Pharma U.S., INC. | $113.19 | 2021-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.00 | 2023-2025 | Jardiance |
| Genzyme Corporation | $99.81 | 2023-2024 | |
| Daiichi Sankyo INC. | $92.26 | 2022-2023 | Injectafer |
| Glaxosmithkline, LLC. | $91.40 | 2021-2024 | Benlysta |
| La Jolla Pharmaceutical Company | $89.29 | 2022 | |
| Ani Pharmaceuticals, INC. | $62.41 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.03 | 2019-2021 | |
| Novo Nordisk INC | $43.55 | 2024 | Rybelsus, Ozempic |
| Veloxis Pharmaceuticals, INC. | $39.35 | 2022-2023 | Envarsus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.07 | 2025 | |
| Ardelyx, INC. | $18.86 | 2025 | Ibsrela |
| Nxstage Medical, INC. | $18.17 | 2024 | |
| Pfizer INC. | $18.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.